MicroRNA regulation as a therapeutic strategy for cardiovascular disease

Current Drug Targets

Volumn 11, Issue 8, 2010, Pages 936-942

  Montgomery, Rusty L ^a   van Rooij, Eva ^a  

^a miRagen Therapeutics Inc   (United States)

Author keywords

Anti miR; Cardiovascular disease; Gene regulation; Heart failure; microRNA; miRNA; Oligonucleotides; Therapeutics

Indexed keywords

MESSENGER RNA; MICRORNA; UNTRANSLATED RNA; ANTISENSE OLIGONUCLEOTIDE;

3' UNTRANSLATED REGION; ANGIOGENESIS; APOPTOSIS; ARTICLE; CARDIOVASCULAR DISEASE; GENE IDENTIFICATION; GENETIC REGULATION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HUMAN; LOSS OF FUNCTION MUTATION; NONHUMAN; PHENOTYPE; RNA BINDING; RNA DEGRADATION; RNA TRANSLATION; SEQUENCE ANALYSIS; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; REVIEW; RNA PROCESSING;

ANIMALS; BASE SEQUENCE; CARDIOVASCULAR DISEASES; GENE EXPRESSION REGULATION; HUMANS; MICE; MICRORNAS; OLIGONUCLEOTIDES, ANTISENSE; RNA PROCESSING, POST-TRANSCRIPTIONAL;

EID: 77956892038     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945010791591368     Document Type: Article

References (48)

1. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 117(4): e25-146.
2. van Rooij E, Olson EN. MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. J Clin Invest 2007; 117(9): 2369-76.
3. van Rooij E, Olson EN. Searching for miR-acles in cardiac fibrosis. Circ Res 2009; 104(2): 138-40.
4. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116(2): 281-97.
5. da Costa Martins PA, Leptidis S, Salic K, De Windt LJ. MicroRNA regulation in cardiovascular disease. Curr Drug Targets 2010; 11(8): 900-6.
6. van Rooij E, Sutherland LB, Liu N, et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci USA 2006; 103(48):18255-60.
7. van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 2007; 316(5824): 575-9.
8. Yang B, Lin H, Xiao J, et al. The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med 2007; 13(4): 486-91.
9. Zhao Y, Ransom JF, Li A, et al. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell 2007; 129(2): 303-17.
10. Liu N, Bezprozvannaya S, Williams AH, et al. microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev 2008; 22(23): 3242-54.
11. Callis TE, Pandya K, Seok HY, et al. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J Clin Invest 2009; 119(9): 2772-86.
12. Ren XP, Wu J, Wang X, et al. MicroRNA-320 is involved in the regulation of cardiac ischemia/reperfusion injury by targeting heat-shock protein 20. Circulation 2009; 119(17): 2357-66.
13. Wang S, Aurora AB, Johnson BA, et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell 2008; 15(2): 261-71.
14. Boettger T, Beetz N, Kostin S, et al. Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster. J Clin Invest 2009; 119(9): 2634-47.
15. Elia L, Quintavalle M, Zhang J, et al. The knockout of miR-143 and -145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease. Cell Death Differ 2009; 16(12): 1590-8.
16. Xin M, Small EM, Sutherland LB, et al. MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury. Genes Dev 2009; 23(18): 2166-78.
17. Cheng Y, Ji R, Yue J, et al. MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy? Am J Pathol 2007; 170(6): 1831-40.
18. Ikeda S, Kong SW, Lu J, et al. Altered microRNA expression in human heart disease. Physiol Genom 2007; 31(3): 367-73.
19. Sayed D, Hong C, Chen IY, Lypowy J, Abdellatif M. MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ Res 2007; 100(3): 416-24.
20. Tatsuguchi M, Seok HY, Callis TE, et al. Expression of microRNAs is dynamically regulated during cardiomyocyte hypertrophy. J Mol Cell Cardiol 2007; 42(6): 1137-41.
21. Thum T, Galuppo P, Wolf C, et al. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation 2007; 116(3): 258-67.
22. van Rooij E, Olson EN. microRNAs put their signatures on the heart. Physiol Genom 2007; 31(3): 365-6.
23. Matkovich SJ, Van Booven DJ, Youker KA, et al. Reciprocal regulation of myocardial microRNAs and messenger RNA in human cardiomyopathy and reversal of the microRNA signature by biomechanical support. Circulation 2009; 119(9): 1263-71.
24. van Rooij E, Sutherland LB, Thatcher JE, et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA 2008; 105(35): 13027-32.
25. Ikeda S, Pu WT. Expression and function of MicroRNAs in heart disease. Curr Drug Targets 2010; 11(8): 913-25.
26. Latronico MVG, Condorelli G. MicroRNAs and cardiac conduction - Therapeutic options. Curr Drug Targets 2010; 11(8): 907-12.
27. Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005; 438(7068): 685-9.
28. Xiao J, Yang B, Lin H, Lu Y, Luo X, Wang Z. Novel approaches for gene-specific interference via manipulating actions of microRNAs: examination on the pacemaker channel genes HCN2 and HCN4. J Cell Physiol 2007; 212(2): 285-92.
29. Manoharan M. 2'-carbohydrate modifications in antisense oligonucleotide therapy: importance of conformation, configuration and conjugation. Biochim Biophys Acta 1999; 1489(1): 117-30.
30. Prakash TP, Bhat B. 2'-Modified oligonucleotides for antisense therapeutics. Curr Top Med Chem 2007; 7(7): 641-9.
31. Stenvang J, Kauppinen S. MicroRNAs as targets for antisense- based therapeutics. Expert Opin Biol Ther 2008; 8(1): 59-81.
32. Weiler J, Hunziker J, Hall J. Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease? Gene Ther 2006; 13(6): 496-502.
33. Hutvagner G, Simard MJ, Mello CC, Zamore PD. Sequence- specific inhibition of small RNA function. PLoS Biol 2004; 2(4): E98.
34. Esau C, Davis S, Murray SF, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006; 3(2): 87-98.
35. Elmen J, Lindow M, Silahtaroglu A, et al. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res 2008; 36(4): 1153-62.
36. van Rooij E, Liu N, Olson EN. MicroRNAs flex their muscles. Trends Genet 2008; 24(4): 159-66.
37. Care A, Catalucci D, Felicetti F, et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med 2007; 13(5): 613-618.
38. Matkovich SJ, Wang W, Tu Y, et al. MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. Circ Res 2010; 106: 166-175.
39. Thum T, Gross C, Fiedler J, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008; 456(7224): 980-4.
40. Yin C, Wang X, Kukreja RC. Endogenous microRNAs induced by heat-shock reduce myocardial infarction following ischemia-reperfusion in mice. FEBS Lett 2008; 582(30): 4137-42.
41. Cheng Y, Liu X, Zhang S, Lin Y, Yang J, Zhang C. MicroRNA-21 protects against the H(2)O(2)-induced injury on cardiac myocytes via its target gene PDCD4. J Mol Cell Cardiol 2009; 47(1): 5-14.
42. Jazbutyte V, Thum T. MicroRNA-21: from cancer to cardiovascular disease. Curr Drug Targets 2010; 11(8): 926-35.
43. Bonauer A, Carmona G, Iwasaki M, et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science 2009; 324(5935): 1710-3.
44. Bonauer A, Boon RA, Dimmeler S. Vascular microRNAs. Curr Drug Targets 2010; 11(8): 943-49.
45. Weber C, Schober A, Zernecke A. MicroRNAs in arterial remodelling, inflammation and atherosclerosis. Curr Drug Targets 2010; 11(8): 950-56.
46. Lin Z, Murtaza I, Wang K, Jiao J, Gao J, Li PF. miR-23a functions downstream of NFATc3 to regulate cardiac hypertrophy. Proc Natl Acad Sci USA 2009; 106(29): 12103-8.
47. Fan GC, Ren X, Qian J, et al. Novel cardioprotective role of a small heat-shock protein, Hsp20, against ischemia/reperfusion injury. Circulation 2005; 111(14): 1792-9.
48. van Rooij E, Quiat D, Johnson BA, et al. A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance. Dev Cell 2009; 17(5): 662-73.